EICHORCondition: Pheochromocytomas · Paragangliomas · Sponsor: Azienda USL Reggio Emilia - IRCCS
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This multicenter retrospective Italian study evaluates the efficacy and safety of PRRT in patients with advanced, unresectable or metastatic pheochromocytomas and paragangliomas (PPGL). Data from \~210 patients treated between 2000 and 2024 will be analyzed. The primary endpoint is disease control rate (DCR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), and prognostic factors.
This description comes directly from the study's public registry record.
Angelina Filice, MD · 0522 296313 · angelina.filice@ausl.re.it
Always discuss trial participation with your own doctor first.
| Policlinico di Bari | Bari, Italy | — |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna, Italy | — |
| Azienda Ospedaliero-Universitaria di Ferrara | Ferrara, Italy | — |
| Irst Irccs | Meldola, Italy | — |
| Fondazione IRCCS Istituto Nazionale dei Tumori di Milano | Milan, Italy | — |
| Istituto Europeo di Oncologia | Milan, Italy | — |
| Azienda Ospedaliero-Universitaria Policlinico di Modena | Modena, Italy | — |
| Istituto Nazionale Tumori IRCCS Fondazione G. Pascale | Naples, Italy | — |
| Università degli Studi di Napoli Federico II | Naples, Italy | — |
| Azienda USL IRCCS di Reggio Emilia | Reggio Emilia, Italy | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07538791